Bio Spec Overview
Ignite Creation Date:
2025-12-24 @ 12:42 PM
Last Modification Date:
2025-12-24 @ 12:42 PM
Retention:
SAMPLES_WITH_DNA
Description:
A blood sample will be obtained for all participants at enrollment to be shipped to a central repository for testing.
In all samples resulting positive to CMV-DNAemia, an additional aliquot of the same sample will be pre-treated with DNase prior to DNA extraction, to exclude DNA which is not protected by a viral capsid (e.g., concatemeric DNA) from Real Time-PCR amplification, thus inducing the loss of non-infectious viral DNA.
The quantification of CMV-RNA and TTV-DNAemia will be carried at T0 and every month during and after letermovir prophylaxis up to the end of study period.
In all samples resulting positive to CMV-DNAemia, an additional aliquot of the same sample will be pre-treated with DNase prior to DNA extraction, to exclude DNA which is not protected by a viral capsid (e.g., concatemeric DNA) from Real Time-PCR amplification, thus inducing the loss of non-infectious viral DNA.
The quantification of CMV-RNA and TTV-DNAemia will be carried at T0 and every month during and after letermovir prophylaxis up to the end of study period.
Section:
A blood sample will be obtained for all participants at enrollment to be shipped to a central repository for testing.
In all samples resulting positive to CMV-DNAemia, an additional aliquot of the same sample will be pre-treated with DNase prior to DNA extraction, to exclude DNA which is not protected by a viral capsid (e.g., concatemeric DNA) from Real Time-PCR amplification, thus inducing the loss of non-infectious viral DNA.
The quantification of CMV-RNA and TTV-DNAemia will be carried at T0 and every month during and after letermovir prophylaxis up to the end of study period.